An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria

BACKGROUND: The FIDELIO-DKD and FIGARO-DKD randomized clinical trials (RCTs) showed finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA), reduced the risk of renal and cardiovascular events in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Us...

Descripción completa

Detalles Bibliográficos
Autores principales: Bramlage, Peter, Lanzinger, Stefanie, Mühldorfer, Steffen, Milek, Karsten, Gillessen, Anton, Veith, Roman, Ohde, Tobias, Danne, Thomas, Holl, Reinhard W., Seufert, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169333/
https://www.ncbi.nlm.nih.gov/pubmed/37158855
http://dx.doi.org/10.1186/s12933-023-01840-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169333/
https://www.ncbi.nlm.nih.gov/pubmed/37158855
http://dx.doi.org/10.1186/s12933-023-01840-5

Ejemplares similares